Your session is about to expire
← Back to Search
Active Treatment: HU6 Planned doses of HU6; N = 31 for Heart Failure (HFpEF Trial)
HFpEF Trial Summary
This trial is testing a new drug (HU6) to see if it is safe and effective. People taking the drug will be compared to people taking a placebo.
- Heart Failure
HFpEF Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowHFpEF Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2021 Phase 2 trial • 80 Patients • NCT04874233HFpEF Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have a currently active autoimmune disease affecting your connective tissues.You have to meet at least one of the following criteria for heart failure:You have a specific type of heart condition called primary cardiomyopathy as determined by the doctor.You have a current case of heart inflammation, either caused by COVID or another reason.You have a serious problem with one of the valves in your heart, as determined by the doctor.You have started taking a certain type of medication called GLP-1 receptor antagonist within the past year.You have a serious heart rhythm problem that has not been treated yet and could be life-threatening.Your doctor believes that you have less than one year to live for reasons unrelated to heart problems.The doctor thinks you have signs and symptoms of heart failure, and your condition meets certain criteria to determine how severe it is.
- Group 1: Placebo Comparator Non-active study drug N = 31
- Group 2: Active Treatment: HU6 Planned doses of HU6; N = 31
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: You will receive the treatment for 4 Months
- Follow Ups: You may be asked to continue sharing information regarding the trial for 14 Months after you stop receiving the treatment.
Frequently Asked Questions
Is the enrollment window for this experiment currently ajar?
"As of today, the clinical trial is still open for participants. The study was first made available to prospective patients on September 30th 2022 and has been updated as recently as September 27th 2022."
What is the size of the cohort engaged in this research?
"Affirmative, the publicly available information on clinicaltrials.gov states that this research trial is actively seeking participants. This initiative began recruiting on September 30th 2022 and was recently updated on September 27th 2022. The study requires 62 patients from 4 distinct sites to be accepted into the program."
How widely dispersed is this trial across North America?
"There are 4 clinical sites that are taking part in this trial. These include Wake Forest located in Winston-Salem, University of Texas Southwestern situated in Dallas, and New Generation of Medical Research found near Hialeah; plus 1 other medical centre."
Has the FDA authorized Active Treatment: HU6 Planned doses of HU6; N = 31 ?
"Our experts at Power gave Active Treatment: HU6 Planned doses of HU6; N = 31 a score of 2 due to its Phase 2 status, which implies that there is some data demonstrating safety but none for efficacy."
Who else is applying?
What state do they live in?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
What questions have other patients asked about this trial?
Why did patients apply to this trial?
How responsive is this trial?
Typically responds via
Average response time
- < 2 Days
Most responsive sites:
- Northwestern University: < 48 hours
Share this study with friends
Copy Link
Messenger